MT10109L in the Treatment of Lateral Canthal Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

February 27, 2020

Study Completion Date

January 25, 2021

Conditions
Lateral Canthal Lines
Interventions
DRUG

MT10109L

MT10109L will be injected into the LCL.

DRUG

Placebo

Placebo will be injected into the LCL.

Trial Locations (14)

10016

Laser Skin Surgery Center of New York, New York

21030

MD Laser, Skin, & Vein Institute, Hunt Valley

22209

SkinDC, Arlington

23502

Virginia Clinical Research, Inc., Norfolk

33146

Skin Research Institute LLC, Coral Gables

70006

Coleman Dermatologic Surgery Center, Metairie

77401

Bellaire Dermatology Associates, Bellaire

85308

Advanced Research Associates, Glendale

92663

Eye Research Foundation, Newport Beach

127473

Moscow scientific-practical centre of dermatovenerology and cosmetology, Moscow

194291

State Budget Institution of Higher Education North-Western State Medical University named after I.I Mechnikov, Saint Petersburg

SK9 7ES

Expert Aesthetics Ltd, Alderley Edge

ML5 3AP

Waverley Medical Practice, Coatbridge

B74 2UG

Medizen Clinic, Sutton Coldfield

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03785145 - MT10109L in the Treatment of Lateral Canthal Lines | Biotech Hunter | Biotech Hunter